SE0102616D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0102616D0
SE0102616D0 SE0102616A SE0102616A SE0102616D0 SE 0102616 D0 SE0102616 D0 SE 0102616D0 SE 0102616 A SE0102616 A SE 0102616A SE 0102616 A SE0102616 A SE 0102616A SE 0102616 D0 SE0102616 D0 SE 0102616D0
Authority
SE
Sweden
Prior art keywords
novel compounds
therapy
processes
formula
preparation
Prior art date
Application number
SE0102616A
Other languages
English (en)
Swedish (sv)
Inventor
Alan Faull
Craig Johnstone
Jeffrey Philip Poyser
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102616A priority Critical patent/SE0102616D0/xx
Publication of SE0102616D0 publication Critical patent/SE0102616D0/xx
Priority to CA2454703A priority patent/CA2454703C/fr
Priority to BR0211473-9A priority patent/BR0211473A/pt
Priority to ES02751935T priority patent/ES2351436T3/es
Priority to AU2002355245A priority patent/AU2002355245B2/en
Priority to EP02751935A priority patent/EP1421074B1/fr
Priority to PCT/SE2002/001403 priority patent/WO2003010158A1/fr
Priority to IL16002802A priority patent/IL160028A0/xx
Priority to JP2003515517A priority patent/JP4571800B2/ja
Priority to PT02751935T priority patent/PT1421074E/pt
Priority to KR1020047001154A priority patent/KR100931172B1/ko
Priority to DK02751935.4T priority patent/DK1421074T3/da
Priority to NZ530750A priority patent/NZ530750A/en
Priority to US10/484,569 priority patent/US7125896B2/en
Priority to CNB028158369A priority patent/CN1263751C/zh
Priority to DE60237828T priority patent/DE60237828D1/de
Priority to MXPA04000756A priority patent/MXPA04000756A/es
Priority to AT02751935T priority patent/ATE482944T1/de
Priority to IL160028A priority patent/IL160028A/en
Priority to ZA200400492A priority patent/ZA200400492B/en
Priority to NO20040313A priority patent/NO326684B1/no
Priority to HK05103629A priority patent/HK1071129A1/xx
Priority to US11/516,225 priority patent/US7956084B2/en
Priority to CY20101101069T priority patent/CY1111543T1/el
Priority to US12/977,640 priority patent/US20110152234A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0102616A 2001-07-25 2001-07-25 Novel compounds SE0102616D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0102616A SE0102616D0 (sv) 2001-07-25 2001-07-25 Novel compounds
AT02751935T ATE482944T1 (de) 2001-07-25 2002-07-19 Neue verbindungen
KR1020047001154A KR100931172B1 (ko) 2001-07-25 2002-07-19 신규 화합물
NZ530750A NZ530750A (en) 2001-07-25 2002-07-19 Novel thiophene carboxamide compounds and their use as pharmaceuticals
ES02751935T ES2351436T3 (es) 2001-07-25 2002-07-19 Nuevos compuestos.
AU2002355245A AU2002355245B2 (en) 2001-07-25 2002-07-19 Novel compounds
EP02751935A EP1421074B1 (fr) 2001-07-25 2002-07-19 Nouveaux composes
PCT/SE2002/001403 WO2003010158A1 (fr) 2001-07-25 2002-07-19 Nouveaux composes
IL16002802A IL160028A0 (en) 2001-07-25 2002-07-19 Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions containing them and their use in therapy
JP2003515517A JP4571800B2 (ja) 2001-07-25 2002-07-19 新規化合物
PT02751935T PT1421074E (pt) 2001-07-25 2002-07-19 Novos compostos
CA2454703A CA2454703C (fr) 2001-07-25 2002-07-19 Nouveaux composes
DK02751935.4T DK1421074T3 (da) 2001-07-25 2002-07-19 Nye forbindelser
BR0211473-9A BR0211473A (pt) 2001-07-25 2002-07-19 Novos compostos
US10/484,569 US7125896B2 (en) 2001-07-25 2002-07-19 Thiophene carboxamide compounds as inhibitors of enzyme IKK-2
CNB028158369A CN1263751C (zh) 2001-07-25 2002-07-19 新化合物
DE60237828T DE60237828D1 (de) 2001-07-25 2002-07-19 Neue verbindungen
MXPA04000756A MXPA04000756A (es) 2001-07-25 2002-07-19 Nuevos compuestos.
ZA200400492A ZA200400492B (en) 2001-07-25 2004-01-22 Novel compounds.
IL160028A IL160028A (en) 2001-07-25 2004-01-22 Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
NO20040313A NO326684B1 (no) 2001-07-25 2004-01-23 Nye tiofenkarboksamidderivater, fremgangsmåte for fremstilling derav, farmasøytiske sammensetninger som inneholder slike derivater, samt deres anvendelse ved terapi
HK05103629A HK1071129A1 (en) 2001-07-25 2005-04-27 Novel compounds
US11/516,225 US7956084B2 (en) 2001-07-25 2006-09-06 Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2
CY20101101069T CY1111543T1 (el) 2001-07-25 2010-11-25 Νεες ενωσεις
US12/977,640 US20110152234A1 (en) 2001-07-25 2010-12-23 Novel Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102616A SE0102616D0 (sv) 2001-07-25 2001-07-25 Novel compounds

Publications (1)

Publication Number Publication Date
SE0102616D0 true SE0102616D0 (sv) 2001-07-25

Family

ID=20284944

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102616A SE0102616D0 (sv) 2001-07-25 2001-07-25 Novel compounds

Country Status (22)

Country Link
US (3) US7125896B2 (fr)
EP (1) EP1421074B1 (fr)
JP (1) JP4571800B2 (fr)
KR (1) KR100931172B1 (fr)
CN (1) CN1263751C (fr)
AT (1) ATE482944T1 (fr)
AU (1) AU2002355245B2 (fr)
BR (1) BR0211473A (fr)
CA (1) CA2454703C (fr)
CY (1) CY1111543T1 (fr)
DE (1) DE60237828D1 (fr)
DK (1) DK1421074T3 (fr)
ES (1) ES2351436T3 (fr)
HK (1) HK1071129A1 (fr)
IL (2) IL160028A0 (fr)
MX (1) MXPA04000756A (fr)
NO (1) NO326684B1 (fr)
NZ (1) NZ530750A (fr)
PT (1) PT1421074E (fr)
SE (1) SE0102616D0 (fr)
WO (1) WO2003010158A1 (fr)
ZA (1) ZA200400492B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
JP4544857B2 (ja) * 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003037886A2 (fr) * 2001-10-30 2003-05-08 Pharmacia Corporation Derives de carboxamide heteroaromatique destines au traitement des inflammations
JP2005531608A (ja) 2002-06-06 2005-10-20 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
AU2003300832A1 (en) * 2002-12-06 2004-06-30 Smithkline Beecham Corporation NF-KappaB INHIBITORS
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US7595316B2 (en) * 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
EP1660474B1 (fr) * 2003-08-15 2008-10-29 AstraZeneca AB Thiophenes substitues et leurs utilisations
US7557215B2 (en) * 2003-12-23 2009-07-07 Somanta Limited Anthraquinone compounds as anti cancer compounds
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2005105777A1 (fr) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Composes d'amide a substitution de thiophene pour le traitement de l'inflammation.
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
DE102005029382B3 (de) * 2005-06-24 2006-12-21 Sanofi-Aventis Deutschland Gmbh Alkoxymethylyl-substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2613068A1 (fr) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Indole carboxamides en tant qu'inhibiteurs d'ikk2
EP2266561A3 (fr) * 2005-09-07 2011-05-18 Merck Serono S.A. Inhibiteurs de l'IKK pour le traitement de l'endométriose
EP3205644A1 (fr) 2005-12-29 2017-08-16 Celtaxsys Inc. Dérivés de diamine en tant qu'inhibiteurs d'hydrolase a4 de leucotriène
WO2008002246A1 (fr) * 2006-06-28 2008-01-03 Astrazeneca Ab Composition pharmaceutique comprenant un inhibiteur de la ikk2 et un second ingrédient actif
WO2008053185A1 (fr) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. Inhibiteurs de la sérine-thréonine protéine kinase ikk-β
AU2007315943A1 (en) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. IKK-beta serine-threonine protein kinase inhibitors
KR20090086081A (ko) * 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
PL2119703T3 (pl) * 2007-01-15 2013-04-30 Santen Pharmaceutical Co Ltd Nowe pochodne indolu o aktywności hamującej kinazę-ßIκB
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
BRPI0911480A2 (pt) * 2008-04-26 2018-04-03 Chroma Therapeutics Ltd inibidores de proteínas serina-treonina quinase ikk-beta
AU2009260389A1 (en) * 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2314575B1 (fr) * 2008-07-14 2013-06-19 Santen Pharmaceutical Co., Ltd Nouveau dérivé d'indole comportant un groupe carbamoyle, un groupe uréido et un groupe oxy substitué
JP5312466B2 (ja) 2008-10-02 2013-10-09 旭化成ファーマ株式会社 ８位置換イソキノリン誘導体及びその用途
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
BRPI1013328A2 (pt) * 2009-04-16 2016-03-29 Telik Inc 4-amino-benzoil-2-(fenilamino) tiofeno-3-carbonitrilas substituídas e 4-a-mino-5benzoil-2-(fenilamino) tiofeno-3-carboxamidas substituídas como inibidores da polimerização de tubulina
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011030139A1 (fr) 2009-09-11 2011-03-17 Astrazeneca Ab Derives de 4-(pyrimidin-2-yl)-piperazine et de 4-(pyrimidin-2-yl)-piperidine utilises en tant que modulateurs du gpr119
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
CN101812007B (zh) * 2010-04-27 2011-11-23 浙江大学 氨基吡咯类化合物及其制备方法
JP2012176930A (ja) * 2010-10-07 2012-09-13 Santen Pharmaceut Co Ltd ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR102071278B1 (ko) * 2012-03-14 2020-03-03 머크 샤프 앤드 돔 코포레이션 Cgrp 수용체 길항제의 제조 방법
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
EP2970309A4 (fr) 2013-03-14 2016-11-09 Celtaxsys Inc Inhibiteurs de la leucotriène a4 hydrolase
EP2968265A4 (fr) 2013-03-14 2016-12-28 Celtaxsys Inc Inhibiteurs de la leucotriène a4 hydrolase
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2821791A1 (fr) * 2013-07-04 2015-01-07 Université de Strasbourg Composés 3-aryl propiolonitrile pour marquage de thiol
AU2014337314B2 (en) * 2013-10-17 2018-12-13 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
JP6344923B2 (ja) * 2014-01-29 2018-06-20 株式会社Uacj 高強度アルミニウム合金及びその製造方法
CN106170480B (zh) * 2014-05-09 2019-09-20 上海科胜药物研发有限公司 新的沃替西汀中间体及其合成方法
WO2018183712A1 (fr) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Composés de pyrrolo[1,2-b]pyridazine et compositions utiles pour traiter des troubles liés à kit et pdgfr
EP3801559A4 (fr) 2018-05-31 2022-03-02 Celltaxis, LLC Procédé de réduction d'exacerbations pulmonaires chez des patients atteints d'une maladie respiratoire
FI3856341T3 (fi) 2019-04-12 2023-11-30 Blueprint Medicines Corp (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä
HRP20240702T1 (hr) 2019-04-12 2024-08-16 Blueprint Medicines Corporation Pripravci i metode za liječenje bolesti posredovanih kitom i pdgfra

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
GB2195634B (en) * 1986-10-01 1990-08-15 Roussel Lab Ltd Thiophene derivatives
JPH02193990A (ja) * 1989-01-20 1990-07-31 Taisho Pharmaceut Co Ltd チオフェンカルボン酸誘導体
US5258357A (en) * 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5571810A (en) * 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
JPH09194476A (ja) * 1996-01-12 1997-07-29 Taisho Pharmaceut Co Ltd チオフェンアルカン酸誘導体
EP0912548A1 (fr) 1996-07-11 1999-05-06 Pfizer Inc. Composes de pyridylpyrrole utiles comme antagonistes de l'interleukine et du facteur tnf
PT853083E (pt) 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6037340A (en) 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU2713799A (en) 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
BR9911914B1 (pt) * 1998-07-08 2010-10-19 n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US20040024047A1 (en) * 2001-10-12 2004-02-05 Callahan James F. Nf-kb inhibitors
EP1324759A4 (fr) 2000-10-12 2004-05-12 Smithkline Beecham Corp Inhibiteurs du nf-g(k)b
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
JP4544857B2 (ja) * 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003029241A1 (fr) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de chk1 kinase
WO2003028731A1 (fr) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de kinase chk1
JP2005506334A (ja) * 2001-10-04 2005-03-03 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
TWI281916B (en) * 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
CA2454703C (fr) 2011-01-04
NZ530750A (en) 2005-08-26
JP4571800B2 (ja) 2010-10-27
DK1421074T3 (da) 2010-12-13
US20110152234A1 (en) 2011-06-23
KR100931172B1 (ko) 2009-12-11
NO326684B1 (no) 2009-01-26
US7125896B2 (en) 2006-10-24
US20040242573A1 (en) 2004-12-02
CY1111543T1 (el) 2015-08-05
KR20040018520A (ko) 2004-03-03
IL160028A0 (en) 2004-06-20
CN1263751C (zh) 2006-07-12
AU2002355245B2 (en) 2008-05-15
NO20040313L (no) 2004-03-25
CA2454703A1 (fr) 2003-02-06
EP1421074A1 (fr) 2004-05-26
CN1541214A (zh) 2004-10-27
US7956084B2 (en) 2011-06-07
US20070015819A1 (en) 2007-01-18
ZA200400492B (en) 2005-04-22
PT1421074E (pt) 2010-11-29
WO2003010158A1 (fr) 2003-02-06
JP2005503372A (ja) 2005-02-03
EP1421074B1 (fr) 2010-09-29
DE60237828D1 (de) 2010-11-11
IL160028A (en) 2012-01-31
HK1071129A1 (en) 2005-07-08
ES2351436T3 (es) 2011-02-04
BR0211473A (pt) 2004-10-26
ATE482944T1 (de) 2010-10-15
MXPA04000756A (es) 2004-04-20

Similar Documents

Publication Publication Date Title
SE0102616D0 (sv) Novel compounds
MXPA04000755A (es) Nuevos compuestos.
GB0003154D0 (en) Novel compounds
HK1082250A1 (en) Thiophene carboxamides as inhibitors of the enzymeikk-2
SE0102439D0 (sv) New compounds
SE0302811D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
SE0202133D0 (sv) Novel compounds
SE0302116D0 (sv) Novel compounds
SE0300092D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
SE0100569D0 (sv) New compounds
SE0303541D0 (sv) New compounds
SE0101038D0 (sv) Novel compounds
SE0303280D0 (sv) Novel compounds
SE0303090D0 (sv) Novel compounds
SE0302755D0 (sv) Novel compounds
SE0002330D0 (sv) Novel compounds